Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph early_phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
2(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (100.0%)

Trials by Status

active_not_recruiting150%
recruiting150%

Recent Activity

2 active trials
Showing 2 of 2
active_not_recruitingearly_phase_1

UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects

NCT06272253
recruitingearly_phase_1

UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)

NCT06259578

Clinical Trials (2)

Showing 2 of 2 trials
NCT06272253Early Phase 1

UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects

Active Not Recruiting
NCT06259578Early Phase 1

UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2